MedCity News February 28, 2025
The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.
Over the past year, several global biopharmaceutical firms have substantially reorganized their health economics and outcomes research (HEOR) groups. Specifically, the leaders of the groups have been let go and the balance of the teams have been dispersed into other functions, typically Market Access or Medical Affairs. Corporate reorganizations are nothing new, but the targeted reorganization of HEOR groups comes at a time of significant change in the operational and...
Today's Sponsors
Today's Sponsor